KrekelsEHTibboelDde WildtSNCeelieIDahanAvan DijkMet alEvidence-based morphine dosing for postoperative neonates and infants
As cagrilintide is still under investigation and not yet approved for general clinical use, standardized dosing guidelines have not been finalized
Milk Thistle Milk thistle (more specifically, silymarin), while a somewhat common supplement found on supplement store shelves these days, is primarily known for its ability to help support the liver thanks to its naturally high antioxidant properties
Creatine monohydrate, one of the most rigorously studied ergogenic and neuroprotective compounds available without prescription, has specific relevance to perimenopausal women that extends beyond athletic performance
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
C., Freeman, M
